Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two better than one where lowering blood pressure is concerned

15.03.2004


A new set of guidelines for lowering blood pressure has been published by the British Hypertension Society (BHS) today. Their main recommendation is that most people with hypertension should be on two blood pressure lowering drugs rather than one.



The guidelines which are aimed at UK doctors, are published in summary form in the BMJ today (12 March), and represent best practice in treating UK patients for hypertension.

People with a blood pressure higher than 140/90 (mm Hg) are classified as having high blood pressure or hypertension.


Some 42 per cent of people in the UK aged between 35 and 64 are estimated to have hypertension, which puts them at a greatly increased risk of heart attacks and strokes.

Basing their guidelines on new data from clinical trials and safety tests of anti-hypertensive drugs, the guidelines say that for the best results in the UK, doctors must aim to get the blood pressure of their patients as low as possible, and for many that means taking a combination of the presently available drugs.

BHS President, Professor Neil Poulter of Imperial College London and St Mary’s hospital, Paddington, and co-author of the BMJ paper said:

"We suggest that two-thirds of people with hypertension should be on two drugs not one to get them down to their target blood pressure.

"But we know that 60 per cent of people on treatment for hypertension are receiving just one blood pressure lowering drug, meaning that many people are missing out on what we consider the best standard of treatment in this country.

The guidelines, authored by the Guidelines Committee of the British Hypertension Society, also suggest a simple ’AB/CD protocol’ to help doctors combine the different classes of blood pressure lowering drugs to provide the best treatment.

For those under 55, they say start with an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker, and then if the target lower blood pressure is not reached, to use either a Calcium channel inhibitor or a Diruretic in addition, until the target is reached.

For those over 55, they suggest starting with a Calcium channel inhibitor or a Diruretic first, and if the target lower blood pressure is not reached, to use an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker in addition.

For black patients they recommend using the same protocol as suggested for those over 55, regardless of patient’s age, as the ’C and D’ drugs are more effective on older people and in the black population than ’A and B’ drugs. This is because older people and black people have less natural renin than non-black (white and asian) and younger people, and C and D drugs work better than A and B where renin levels are low.

The BHS guidelines were last revised in 1999. Specialists in the field representing over 12 different stakeholder organisations including the British Hearth Foundation, the Royal College of General Practitioners and the UK Department of Health contributed to the latest guidelines.


For further information, please contact:

Professor Neil Poulter
International Centre for Circulatory Health
Imperial College London and St Mary’s Hospital, London
Tel: 44-207-594-3446
Email: n.poulter@imperial.ac.uk

Tony Stephenson
Imperial College London Press Office
Tel: 44-207-594-6712
Mobile: 44-775-373-9766
E-mail: at.stephenson@imperial.ac.uk

Tony Stephenson | alfa
Further information:
http://www.imperial.ac.uk
http://www.bmj.com

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Northern oceans pumped CO2 into the atmosphere

27.03.2017 | Earth Sciences

Fingerprint' technique spots frog populations at risk from pollution

27.03.2017 | Life Sciences

Big data approach to predict protein structure

27.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>